TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12595838

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg per day, increased to 150 mg per day after 411 patients enrolled)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Both groups (Metoprolol and Placebo)
Number of subjects: 1000
Study: 10482216

Group type: EXPERIMENTAL
Intervention: Eat Well and Keep Moving Program
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 479
Study: 8599788

Group type: EXPERIMENTAL
Intervention: Lidocaine with sodium bicarbonate (NaHCO3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42
Study: 3048075

Group type: EXPERIMENTAL
Intervention: 50 g glucose and 40 g fat
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 50 g fructose and 40 g fat
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 g sucrose and 40 g fat
Number of subjects: 21

Group type: COMPARATOR
Intervention: 40 g fat alone
Number of subjects: 21
Study: 1098687

Group type: EXPERIMENTAL
Intervention: Dithranol applied to the normal skin surrounding psoriatic lesions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated lesions)
Number of subjects: 36
Study: 31900187

Group type: EXPERIMENTAL
Intervention: Usual care + palliative care (UC + PC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 22
Study: 31609930

Group type: EXPERIMENTAL
Intervention: Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) 50/200/25 mg
Number of subjects: 472

Group type: COMPARATOR
Intervention: Stay on baseline regimen (SBR)
Number of subjects: 472
Study: 27000071

Group type: EXPERIMENTAL
Intervention: TENS therapy for 10 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no TENS therapy)
Number of subjects: 49
Study: 25529995

Group type: EXPERIMENTAL
Intervention: Text message with a stranger
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Text message with a companion
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Distraction condition (mobile phone game)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard perioperative management
Number of subjects: 98
Study: 23826304

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 77036

Group type: COMPARATOR
Intervention: Comparison subjects
Number of subjects: 77036

Group type: EXPERIMENTAL
Intervention: Zolpidem (for >30 days)
Number of subjects: 77036
Study: 22027687

Group type: EXPERIMENTAL
Intervention: BES
Number of subjects: 1707
Study: 18672115

Group type: EXPERIMENTAL
Intervention: Post-abortal insertion and staff training (Period 2)
Number of subjects: 2172

Group type: EXPERIMENTAL
Intervention: Post-abortal insertion, staff training, and simplified screening (Period 3)
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Control period (Period 1)
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Nearby agency (no interventions implemented)
Number of subjects: 2172
Study: 21315635

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 346

Group type: COMPARATOR
Intervention: EQ-5D and SF-6D
Number of subjects: 346
Study: 16028147

Group type: COMPARATOR
Intervention: Mefloquine-artesunate (MAS3)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Standard 4-dose course of dihydroartemisinin-piperaquine (DP4)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Once-daily regimen of dihydroartemisinin-piperaquine (DP3)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP4)
Number of subjects: 499
Study: 11824390

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy with cisplatin based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy with hyperthermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy, cisplatin, and hyperthermia
Number of subjects: 0
Study: 9533120

Group type: EXPERIMENTAL
Intervention: Kinetic assisted venous drainage (KAVD)
Number of subjects: 50
Study: 8308183

Group type: EXPERIMENTAL
Intervention: Oral cat immunotherapy (2.5 x 10(6) allergy units or 436 U Fel d I administered over 3 months)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral cat immunotherapy
Number of subjects: 53
Study: 2740549

Group type: EXPERIMENTAL
Intervention: Physician's advice to quit smoking
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control group (no physician's advice)
Number of subjects: 424
Study: 1092131

Group type: EXPERIMENTAL
Intervention: Oral ferrous iron 2000 mg after each blood donation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oral ferrous iron 1000 mg after each blood donation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo after each blood donation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oral ferrous iron 2000 mg after four months between donations
Number of subjects: 58
Study: 31612475

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Minimal oral intake during nutrition support
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Additional beta lactam antibiotics
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Longer length of hospital stay
Number of subjects: 23
Study: 29763572

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 4287
Study: 26690313

Group type: EXPERIMENTAL
Intervention: BND 600 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: BND 1,200 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: PLB
Number of subjects: 148
Study: 25155931

Group type: EXPERIMENTAL
Intervention: Combined OPRM1 118A>G and COMT 472G>A genotype
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 64
Study: 23121377

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445
Study: 20460233

Group type: EXPERIMENTAL
Intervention: HMB (2 g/d)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 25159904

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (ProActive)
Number of subjects: 365
Study: 16103586

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil-artesunate
Number of subjects: 42
Study: 12441210

Group type: EXPERIMENTAL
Intervention: Nifedipine-CR
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 19
Study: 10065061

Group type: EXPERIMENTAL
Intervention: One-day training course in building and maintaining patients' trust (intervention group)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (physicians not receiving the training)
Number of subjects: 412
Study: 7486087

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 5 micrograms/mL
Number of subjects: 66

Group type: COMPARATOR
Intervention: Epidural fentanyl 10 micrograms/mL
Number of subjects: 66
Study: 2178382

Group type: EXPERIMENTAL
Intervention: Intervention program (training session)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal daily activity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control period (24 hours without exercise training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Training session
Number of subjects: 40
Study: 519838

Group type: EXPERIMENTAL
Intervention: Wright nebulizer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dosimeter-DeVilbiss apparatus
Number of subjects: 20
Study: 31655508

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg tablet given the night before and 1 hour before the operation)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg tablet)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (given at the same times as pregabalin)
Number of subjects: 54
Study: 26124455

Group type: EXPERIMENTAL
Intervention: Post-procedural anticoagulation (AC) for routine prophylaxis (n=869, median duration 4 days)
Number of subjects: 2932

Group type: COMPARATOR
Intervention: No post-procedural anticoagulation (AC) (n=2063)
Number of subjects: 2932

Group type: EXPERIMENTAL
Intervention: Post-procedural anticoagulation (AC) for routine prophylaxis
Number of subjects: 2932
Study: 24121184

Group type: EXPERIMENTAL
Intervention: 50:40:10 mixture of MCT, soybean oil, and fish oil (treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Soybean oil (control)
Number of subjects: 32
Study: 23352857

Group type: EXPERIMENTAL
Intervention: LipoCol Forte capsules or powder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LipoCol Forte
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lovastatin tablets
Number of subjects: 0
Study: 21347767

Group type: EXPERIMENTAL
Intervention: Increased water consumption through lessons on water and provision of water fountains and water bottles (behavioral and environmental intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study: 19876673

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 198
Study: 17298423

Group type: EXPERIMENTAL
Intervention: Standard therapy plus add-on omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 14517707

Group type: EXPERIMENTAL
Intervention: BIA 3-202 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 200 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 400 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BIA 3-202 (all doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11081780

Group type: EXPERIMENTAL
Intervention: Acute salt loading with a 2 h infusion of isotonic saline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic low-, regular-, and high-sodium diet for 1 week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acute water loading
Number of subjects: 24
Study: 8817257

Group type: EXPERIMENTAL
Intervention: Small stimulus followed 50 ms later by large stimulus (masked stimulus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Same stimulus presented without masking (easily perceived)
Number of subjects: 0
Study: 1575145

Group type: EXPERIMENTAL
Intervention: Angled catheter
Number of subjects: 125
Study: 3936056

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (20 mg, 3-times daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sustained-release glyceryl trinitrate (6.4 mg, 3-times daily)
Number of subjects: 50
Study: 30811594

Group type: EXPERIMENTAL
Intervention: Couple CARE program (CCP) for parents of newborns; uncontrolled demonstration project (Study 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Couple CARE program (CCP) for parents of newborns; randomized controlled trial (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Couple CARE program (CCP) for parents of newborns; evaluated with low-income parents from urban hospitals (Study 3 and Study 4)
Number of subjects: 0
Study: 30463925

Group type: EXPERIMENTAL
Intervention: AutoFMT (autologous fecal microbiota transplantation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline enema (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate (Amox-Clav)
Number of subjects: 10
Study: 26656205

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (caloric intake increase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counterfactuals from the model
Number of subjects: 0
Study: 24637411

Group type: EXPERIMENTAL
Intervention: EPA (1800 mg/day) + statin (rosuvastatin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Statin (rosuvastatin) only
Number of subjects: 30
Study: 22465423

Group type: EXPERIMENTAL
Intervention: Community empowerment strategy with four components: organisation and management, entomological risk surveillance, capacity building, and community work for vector control.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Community empowerment strategy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine activities without interference (Control)
Number of subjects: 32
Study: 19268930

Group type: EXPERIMENTAL
Intervention: SureView catheter
Number of subjects: 175

Group type: COMPARATOR
Intervention: Wallace catheter
Number of subjects: 175
Study: 17493557

Group type: EXPERIMENTAL
Intervention: Keeled glenoid components
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pegged glenoid components
Number of subjects: 20
Study: 15982282

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-cardiopulmonary bypass (non-CPB)
Number of subjects: 40
Study: 11945144

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2b interferon (IFN‐R)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Leukocyte alpha n‐3 interferon (IFN‐L)
Number of subjects: 168
Study: 9718470

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg orally once daily for 3 days)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Clarithromycin (7.5 mg/kg orally twice daily for 10 days)
Number of subjects: 174
Study: 7581311

Group type: EXPERIMENTAL
Intervention: Injury-prevention education programs including Window Guards campaign, Safety City Program, KISS, Burn Prevention Curriculum, Smoke Detector Distribution, Harlem Alternative to Violence Program, Adolescent Outreach Program, Critical Incident Stress Management Teams.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Programs providing safe activities and environments including Bicycle Safety Program/Urban Youth Bike Corps, Playground Injury Prevention Program, Greening of Harlem Program, Harlem Horizon Art Studio, Harlem Hospital Dance Clinic, Unity through Murals project, baseball at Harlem Little League, winter baseball clinic, soccer league.
Number of subjects: 0
Study: 2526959

Group type: EXPERIMENTAL
Intervention: Procaterol 0.02 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol 0.2 mg (control)
Number of subjects: 15
Study: 332505

Group type: EXPERIMENTAL
Intervention: practolol 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: practolol 400 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 31070702

Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 796

Group type: COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACEis)
Number of subjects: 796
Study: 31694631

Group type: EXPERIMENTAL
Intervention: Injected dexamethasone
Number of subjects: 13
Study: 28320603

Group type: EXPERIMENTAL
Intervention: Restriction recommendations on diet and physical activities (Group B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No specific counseling on diet or activity (Group A)
Number of subjects: 95
Study: 26416084

Group type: EXPERIMENTAL
Intervention: Supportive leadership training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no supportive leadership training)
Number of subjects: 110
Study: 23743855

Group type: EXPERIMENTAL
Intervention: Self-management intervention with provision of HF educational information
Number of subjects: 902

Group type: COMPARATOR
Intervention: Enhanced education control group receiving the same HF educational materials
Number of subjects: 902
Study: 22267465

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (900/100 mg once daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: raltegravir (400 mg twice daily)
Number of subjects: 19
Study: 19175441

Group type: EXPERIMENTAL
Intervention: Multicomponent practice-change intervention
Number of subjects: 644
Study: 17224706

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-15 mg once daily, starting dose = 9 mg)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 205
Study: 15231013

Group type: EXPERIMENTAL
Intervention: Raloxifene (combined doses of 60 mg/day and 120 mg/day)
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study: 11281249

Group type: EXPERIMENTAL
Intervention: Plant sterols and their derivatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various mixtures of plant sterols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant sterol consumption
Number of subjects: 0
Study: 9733025

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail: 90 mg of Q10 and 13.5 mg of d‐alpha‐tocopheryl acetate daily (18 men)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (19 men)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Number of subjects: 37
Study: 8289481

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) 2 x 10 mg/m2 subcutaneously (s.c.) days 1‐14 plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) 2 x 150 micrograms protein/day s.c. given either following Ara C (days 15‐21) or simultaneously (days 8‐14) for 1‐5 cycles.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside (LD-AraC) alone (not explicitly mentioned but referenced as ongoing evaluation).
Number of subjects: 108
Study: 3188048

Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.30 ppm NO2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined O3 and NO2 exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 24
Study: 1565294

Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplements (800 mg dl‐alpha‐tocopherol acetate) for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 755040

Group type: EXPERIMENTAL
Intervention: methysergide (serotonin receptor blocker)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: methysergide
Number of subjects: 10
Study: 30247332

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal resection (Lap)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Open laparotomy and rectal resection (Open)
Number of subjects: 475
Study: 28086921

Group type: EXPERIMENTAL
Intervention: Web-based nutrition education programme promoting vegetable intake (350 g per day, five small bowls)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Web-based nutrition education programme
Number of subjects: 1500
Study: 25404086

Group type: EXPERIMENTAL
Intervention: sirolimus (SRL) - removed CNI and increased sirolimus
Number of subjects: 45

Group type: COMPARATOR
Intervention: tacrolimus (TAC) - maintained CNI
Number of subjects: 45
Study: 24954343

Group type: EXPERIMENTAL
Intervention: Psychological and music intervention for 30 min before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 23059780

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Erlotinib-bexarotene
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 255
Study: 19438416

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once-daily
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice-daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once-daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice-daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Esomeprazole (once-daily) vs Lansoprazole (once-daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Esomeprazole (twice-daily) vs Lansoprazole (twice-daily)
Number of subjects: 87
Study: 17307447

Group type: EXPERIMENTAL
Intervention: Use of indicated secondary prevention medications (antiplatelet agents, beta-blockers, ACE inhibitors or ARBs, lipid-lowering agents)
Number of subjects: 2970

Group type: EXPERIMENTAL
Intervention: Use of indicated secondary prevention medications
Number of subjects: 2970
Study: 15362759

Group type: EXPERIMENTAL
Intervention: Perioperative music therapy with a key-lighting keyboard system (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 50
Study: 11274935

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 9844956

Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DEX-CRH test
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Psychometric measurements
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Individual assessment
Number of subjects: 54
Study: 7983994

Group type: EXPERIMENTAL
Intervention: Oral homoeopathic immunotherapy to their principal allergen
Number of subjects: 28

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 28
Study: 2689183

Group type: COMPARATOR
Intervention: Clonazepam (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clobazam (20 mg)
Number of subjects: 10
Study: 30057055

Group type: EXPERIMENTAL
Intervention: 10-week Hatha yoga exercise program
Number of subjects: 42

Group type: COMPARATOR
Intervention: 10-week follow-up program (Control)
Number of subjects: 42
Study: 27092784

Group type: COMPARATOR
Intervention: Hickman catheter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TIVAS
Number of subjects: 100
Study: 24149925

Group type: EXPERIMENTAL
Intervention: 40 g of soy flour (whole soy group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 40 g of low-fat milk powder + 63 mg of daidzein (daidzein group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 40 g of low-fat milk powder (placebo group)
Number of subjects: 270
Study: 22990513

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (20/30 made-to-measure) worn during 30 minutes of walking on a treadmill
Number of subjects: 16

Group type: COMPARATOR
Intervention: No compression stockings (control group)
Number of subjects: 16